top of page

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

  • maura169
  • Nov 12, 2019
  • 1 min read

Updated: Sep 13, 2022

Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans




 
 
 

Comentários


DragonflyTherapeutics_Logo_Color_Final_07.09.16.png
Activating the Immune System to Fight Disease
Contact

DRAGONFLY Therapeutics, Inc.
180 3rd Avenue, Sixth Floor

Waltham, MA 02451
United States

1-617-588-0086

Sitemap
  • Twitter
  • LinkedIn

©2024 Dragonfly Therapeutics - All Rights Reserved

bottom of page